Loading...

JAGSNPHARM Jagsonpal Pharmaceuticals Ltd Legal Disputes Announcement

Jgsn

JGSN

Jagsonpal Pharmaceuticals Ltd

(JAGSNPHARM)

2023 Announcement

Show Summary

Summary

Earnings Call Update

Earnings Call Audio

Financial Results Extract

Investor Presentation Update

Employee Stock Options

Analyst Call Scheduled

Compliance Certificate

Investor Meeting

Office Address Change

Annual Compliance Report

Earnings Call Transcript

Financial Results Published

FY25 Earnings Report

FY25 Results Released

Business Agreement Termination

Investor Conference Call

Volume Increase Clarified

Volume Increase Clarification

Compliance Certificate

Customs Order Confirmed

ESOP Share Allotment

Management Changes

Management Appointment

Resignation Announcement

Clarification Submitted

Business Acquisition

USFDA Warning Letter

Equity Share Allotment

Management Changes

Management Change

Q3 Earnings Update

Financial Results Advertise...

Investor Meeting Outcome

Q3 Results Released

Compliance Certificate

CFO Resignation

Investor Meeting

Investor Meeting Scheduled

Postal Ballot Notice

Investor Meeting

Investor Meeting

Earnings Call Scheduled

Financial Results Published

Earnings Call Update

Investor Presentation Update

Related Party Transactions

Share Split Approval

Q2FY25 Financial Results

Compliance Certificate

Investor Conference Call

SEBI Settlement Order

Insider Trading Disclosure

Investor Meeting Scheduled

Investor Agency Appointment

AGM Announcement

AGM Announcement

Employee Stock Options Plan...

Q1FY25 Results Announcement

Jagsonpals CSR Initiative

Sale of Facility

Certificate Submission

Equity Shares Allotted

Acquisition Closure

Financial Results Publication

Compliance Submission

Related Party Transactions ...

Employee Stock Options Grant

FY24 Results Announcement

Acquisition Announcement

Submission of Certificate

Certificate Submission

Compliance Submission

Investor Meeting

Financial Results Advertise...

Financial Results & CFO App...

Compliance Certificate

Equity Shares Allotted

Regulatory Action Notice

Allotment of Equity Shares

Newspaper Publication

Related Party Transactions ...

Earnings Report

Divestment Announcement

CSR Initiative for Womens H...

Certificate under Regulatio...

Clarification on Price Move...

Financial Statements

Financial Statements

Compliance filing

Financial Statements Public...

Employee Stock Options

Related Party Transaction D...

Financial Results

External Links:

Data:

Jagsonpal Pharmaceuticals has received a Demand-cum-Show Cause Notice from the Office of the Principal Commissioner of Customs regarding incorrect classification of imported goods, with a differential duty of Rs.5,09,79,206.

AI Assistant

Jagsonpal Pharmaceuticals Ltd

2023

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.